Showing results (11-20 of 154) with videos related to

Sort By:
Pageof 16
Antiviral Therapy|March 10, 2023
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world settingCharlotte-Paige Rolle, Jamie Castano, Vu Nguyen, et al.
HIV Clinical Trials|February 6, 2010
Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeksDushyantha Jayaweera, Edwin Dejesus, Kim L Nguyen, et al.
Medicine|March 11, 2025
Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide versus a dolutegravir-based regimen among virologically suppressed adults living with HIV through 144 weeksCharlotte-Paige Rolle, Jeffrey Garrett, Jamie Castano, et al.
HIV Clinical Trials|October 29, 2014
Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trialEdwin DeJesus, Gerd Fätkenheuer, Catherine Orrell, et al.
AIDS (London, England)|November 10, 2009
Virologic and immunologic activity of PegIntron in HIV diseaseJonathan B Angel, Wayne Greaves, Jianmin Long, et al.
Antiviral Therapy|April 18, 2014
Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudyGraeme Moyle, Helene Hardy, Jonathan Uy, et al.
The Open AIDS Journal|January 22, 2011
Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week DataAllan E Rodriguez, Edwin Dejesus, Vanessa Williams, et al.
Antiviral Therapy|October 26, 2013
Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761)David A Margolis, Joseph J Eron, Edwin DeJesus, et al.
Antimicrobial Agents and Chemotherapy|September 24, 2008
Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification studyEdwin DeJesus, Michael S Gottlieb, Joseph C Gathe, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL)Nestor Sosa, Christina Hill-Zabala, Edwin Dejesus, et al.
Pageof 16